Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al; Nykode’s $45M place­ment; Ideaya’s post-ES­MO of­fer­ing

Plus, news from Skye Bio­science, Me­di­ar Ther­a­peu­tics and Servi­er.

A first look at Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al: The com­pa­ny said Wednes­day that three pa­tients have been dosed in the Phase I/II study so far, with mild grade 1 side ef­fects re­lat­ed to the ther­a­py, known as EBT-101. Two of the three par­tic­i­pants ex­pe­ri­enced brief el­e­va­tion in liv­er en­zymes, a con­cern re­lat­ed to ther­a­pies like EBT-101 that use vi­ral vec­tors for de­liv­ery. How­ev­er, there were no in­fu­sion-re­lat­ed re­ac­tions or com­ple­ment-me­di­at­ed tox­i­c­i­ty, a type of im­mune re­sponse. The re­sults were pre­sent­ed at the Eu­ro­pean So­ci­ety of Gene & Cell Ther­a­py’s an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER